Literature DB >> 33211271

Naloxone Diminishes the Virulence and Modifies the Cellular Immune Responses of BALB/c Mice Infected with Leishmania major.

Mohammad Hossein Alimohammadian1, Farhad Riazi-Rad2, Mahsa Asadi-Tat2, Sima Darabi2, Haiedeh Darabi2, Vahid Khaze2, Fariborz Bahrami2, Soheila Ajdary2.   

Abstract

PURPOSE: Leishmania major-infected BALB/c mice display strong susceptibility to the infection due to the induction of Th2 response. The aim of this study was to assess the effects of naloxone on virulence of L. major in BALB/c mice and the ensued cellular immune response.
METHODS: The effects of injection of a single dose of naloxone in the footpad of L. major-infected BALB/c mice were investigated by evaluating the lesion sizes, the parasite burden, cell proliferation, secreted cytokines (IFN-γ, IL-4, IL-10 and IL-12) and their genes expressions due to naloxone treatment while the untreated mice were used as a control.
RESULTS: Significantly lower lesion sizes and less parasite burden were measured in the treated mice. Significantly decreased productions of IFN-γ, IL-12, IL-4, and IL-10 were also observed in the treated mice at week 4 post-infection while the production IL-10 remained significantly hindered till 8 weeks post-infection.
CONCLUSION: Our data indicated that although the treatment of L. major-infected BALB/c mice with a single dose of naloxone was unable to improve the cellular immune response, it led to lower virulence, confirmed by significantly reduced lesions and parasite load.

Entities:  

Keywords:  BALB/c mice; Cutaneous leishmaniasis; Leishmania major; Naloxone

Year:  2020        PMID: 33211271     DOI: 10.1007/s11686-020-00308-w

Source DB:  PubMed          Journal:  Acta Parasitol        ISSN: 1230-2821            Impact factor:   1.440


  20 in total

1.  Endomorphin-2 modulates productions of TNF-alpha, IL-1beta, IL-10, and IL-12, and alters functions related to innate immune of macrophages.

Authors:  Yasutaka Azuma; Kiyoshi Ohura
Journal:  Inflammation       Date:  2002-10       Impact factor: 4.092

Review 2.  Cytokines in parasitic diseases: the example of cutaneous leishmaniasis.

Authors:  P Launois; F Tacchini-Cottier; C Parra-Lopez; J A Louis
Journal:  Int Rev Immunol       Date:  1998       Impact factor: 5.311

Review 3.  The immunology of susceptibility and resistance to Leishmania major in mice.

Authors:  David Sacks; Nancy Noben-Trauth
Journal:  Nat Rev Immunol       Date:  2002-11       Impact factor: 53.106

4.  IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice.

Authors:  P Launois; I Maillard; S Pingel; K G Swihart; I Xénarios; H Acha-Orbea; H Diggelmann; R M Locksley; H R MacDonald; J A Louis
Journal:  Immunity       Date:  1997-05       Impact factor: 31.745

Review 5.  Type 1 and type 2 responses to Leishmania major.

Authors:  Kathleen A Rogers; Gregory K DeKrey; M Lamine Mbow; R Dean Gillespie; Claudia I Brodskyn; Richard G Titus
Journal:  FEMS Microbiol Lett       Date:  2002-03-19       Impact factor: 2.742

6.  Morphine-induced degradation of the host defense barrier: role of macrophage injury.

Authors:  M Bhaskaran; K Reddy; S Sharma; J Singh; N Radhakrishnan; A Kapasi; P C Singhal
Journal:  J Infect Dis       Date:  2001-12-03       Impact factor: 5.226

7.  Opioid-mediated suppression of interferon-gamma production by cultured peripheral blood mononuclear cells.

Authors:  P K Peterson; B Sharp; G Gekker; C Brummitt; W F Keane
Journal:  J Clin Invest       Date:  1987-09       Impact factor: 14.808

Review 8.  Intranasal naloxone administration for treatment of opioid overdose.

Authors:  Amanda Robinson; Daniel P Wermeling
Journal:  Am J Health Syst Pharm       Date:  2014-12-15       Impact factor: 2.637

Review 9.  The regulation of immunity to Leishmania major.

Authors:  S L Reiner; R M Locksley
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

Review 10.  Immunobiology of experimental leishmaniasis.

Authors:  I Müller; U Fruth; J A Louis
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.